AU2003230834A8 - Antagonists of il-21 and modulation of il-21-mediated t cell responses - Google Patents

Antagonists of il-21 and modulation of il-21-mediated t cell responses

Info

Publication number
AU2003230834A8
AU2003230834A8 AU2003230834A AU2003230834A AU2003230834A8 AU 2003230834 A8 AU2003230834 A8 AU 2003230834A8 AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A8 AU2003230834 A8 AU 2003230834A8
Authority
AU
Australia
Prior art keywords
antagonists
mediated
modulation
cell responses
responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003230834A
Other versions
AU2003230834A1 (en
Inventor
Terry B Strom
Xin Xiao Zheng
Thomas Moll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2003230834A1 publication Critical patent/AU2003230834A1/en
Publication of AU2003230834A8 publication Critical patent/AU2003230834A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003230834A 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses Abandoned AU2003230834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37103802P 2002-04-09 2002-04-09
US60/371,038 2002-04-09
PCT/US2003/010736 WO2003087320A2 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Publications (2)

Publication Number Publication Date
AU2003230834A1 AU2003230834A1 (en) 2003-10-27
AU2003230834A8 true AU2003230834A8 (en) 2003-10-27

Family

ID=29250623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003230834A Abandoned AU2003230834A1 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Country Status (2)

Country Link
AU (1) AU2003230834A1 (en)
WO (1) WO2003087320A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444363T1 (en) 2001-11-05 2009-10-15 Zymogenetics Inc IL-21 ANTAGONISTS
ES2381265T3 (en) 2002-06-07 2012-05-24 Zymogenetics, Inc. Use of IL-21 and monoclonal antibody to treat solid cancers
MXPA05003729A (en) * 2002-10-11 2005-06-17 Novo Nordisk As Treatment of allergic conditions by use of il 21.
US20060177421A1 (en) * 2002-10-11 2006-08-10 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
JP4664684B2 (en) 2002-12-13 2011-04-06 ザイモジェネティクス， インコーポレイテッド Production of IL-21 in prokaryotic hosts
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1708737A2 (en) * 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
EP1586585A1 (en) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expression system for the production of IL-15/Fc fusion proteins and their use
RU2007102287A (en) * 2004-08-05 2008-09-10 Вайет (Us) INTERLEUKIN-21 RECEPTOR ACTIVITY ANTAGONISTS
ITRM20040586A1 (en) * 2004-11-29 2005-02-28 Giuliani Spa ANTIGENIC EPITOPES OF INTERLEUCHINA-21, RELATIVE ANTIBODIES AND THEIR USE IN MEDICAL FIELD.
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
US8034326B2 (en) 2005-04-18 2011-10-11 Novo Nordisk A/S IL-21 variants
EP2567973B1 (en) 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
US7592427B2 (en) 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
JP2010512769A (en) * 2006-12-21 2010-04-30 ノヴォ ノルディスク アクティーゼルスカブ Interleukin-21 mutant with altered binding to IL-21 receptor
CA2707026C (en) 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2010103038A1 (en) * 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
CN102071192A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA used for curing psoriasis
CN102071198A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
CN102071191A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2665486B1 (en) * 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
US11400134B2 (en) 2015-10-09 2022-08-02 Bioniz, Llc Modulating gamma-c-cytokine activity
KR101928981B1 (en) 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
CN111205361B (en) * 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 Interleukin 21 protein (IL21) mutant and application thereof
CN113874075A (en) 2019-05-03 2021-12-31 比奥尼斯有限责任公司 Effect of modulation of gamma C-cytokine signaling on the treatment of alopecia and alopecia-related disorders

Also Published As

Publication number Publication date
WO2003087320A2 (en) 2003-10-23
WO2003087320A3 (en) 2004-08-26
AU2003230834A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
AU2003230834A8 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
EP1546112A4 (en) Imidazolopyridines and methods of making and using the same
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003288902A8 (en) Microcapsules and methods of use
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003281736A8 (en) Electrodes and related devices
HK1086827A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
AU2003290986A8 (en) Power converter circuitry and method
EP1501514A4 (en) Protein kinase modulators and methods of use
AU2003286657A8 (en) Filters and methods of making and using the same
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
HK1117189A1 (en) Assay cartridges and methods of using the same
HK1079789A1 (en) Vasculostatic agents and methods of use thereof
AU2003286612A1 (en) Satiation implants and methods of use
IL166332A0 (en) Isolation and identification of t cells
EP1519431A4 (en) Electrode and cell comprising the same
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1487033A4 (en) Battery and method of manufacturing the battery
EP1497270A4 (en) Amide compounds and methods of using the same
PL375699A1 (en) Pyrazolopyridines and methods of making and using the same
PL375355A1 (en) Novel lipases and uses thereof
EP1476150A4 (en) Carboxyfullerenes and methods of use thereof
EP1546361A4 (en) Auto-stimulating cells and method for making and using the same
EP1646096A4 (en) Battery pack and method of producing the same
AU2003211585A1 (en) Reaction cell and method of using the cell

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase